Published 4 years ago • loading... • Updated 4 years ago
Pfizer inks $43 billion Seagen deal to boost cancer portfolio
Summary by RTÉ
Pfizer Inc on Monday struck a roughly $43 billion deal for Seagen Inc to bulk up its cancer treatment portfolio, as the drugmaker braces for a steep fall in COVID-19 product sales and loss of exclusivity for some top sellers.